{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T21:26:40Z","timestamp":1789075600651,"version":"build-2803163510"},"reference-count":34,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,11,1]],"date-time":"2016-11-01T00:00:00Z","timestamp":1477958400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"Tehran University of Medical Sciences"},{"name":"Research Council of the University of Tehran"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmacology"],"published-print":{"date-parts":[[2016,11]]},"DOI":"10.1016\/j.ejphar.2016.09.006","type":"journal-article","created":{"date-parts":[[2016,9,8]],"date-time":"2016-09-08T23:01:11Z","timestamp":1473375671000},"page":"274-283","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt\/p53 axis in pre-B acute lymphoblastic leukemia cells"],"prefix":"10.1016","volume":"791","author":[{"given":"Samaneh","family":"Bayati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Davood","family":"Bashash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shahin","family":"Ahmadian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ava","family":"Safaroghli-Azar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kamran","family":"Alimoghaddam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ardeshir","family":"Ghavamzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seyed H.","family":"Ghaffari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejphar.2016.09.006_bib1","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1634\/theoncologist.2014-0229","article-title":"Aprepitant and fosaprepitant: a 10-year review of efficacy and safety","volume":"20","author":"Aapro","year":"2015","journal-title":"Oncologist"},{"key":"10.1016\/j.ejphar.2016.09.006_bib2","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1111\/j.1471-4159.2009.06032.x","article-title":"A constitutively active form of neurokinin 1 receptor and neurokinin 1 receptor mediated apoptosis in glioblastomas","volume":"109","author":"Akazawa","year":"2009","journal-title":"J. Neurochem."},{"key":"10.1016\/j.ejphar.2016.09.006_bib3","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1182\/blood-2009-02-207654","article-title":"Forodesine has high antitumor activity in chronic lymphocytic leukemia and activates p53-independent mitochondrial apoptosis by induction of p73 and BIM","volume":"114","author":"Alonso","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ejphar.2016.09.006_bib4","doi-asserted-by":"crossref","first-page":"2863","DOI":"10.1002\/ijc.24748","article-title":"Akt-mediated regulation of NF\u03baB and the essentialness of NF\u03baB for the oncogenicity of PI3K and Akt","volume":"125","author":"Bai","year":"2009","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ejphar.2016.09.006_bib5","first-page":"299","article-title":"Targeting the PI3K\/AKT\/mTOR signaling axis in children with hematologic malignancies","volume":"14","author":"Barrett","year":"2012","journal-title":"Pediatr. Drugs"},{"key":"10.1016\/j.ejphar.2016.09.006_bib6","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1016\/j.jhep.2013.12.024","article-title":"Hepatoblastoma cells express truncated neurokinin-1 receptor and can be growth inhibited by aprepitant in vitro and in vivo","volume":"60","author":"Berger","year":"2014","journal-title":"J. Hepatol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib7","doi-asserted-by":"crossref","first-page":"e205","DOI":"10.1016\/S1470-2045(12)70580-6","article-title":"Relapsed childhood acute lymphoblastic leukaemia","volume":"14","author":"Bhojwani","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib8","doi-asserted-by":"crossref","first-page":"7256","DOI":"10.1038\/sj.onc.1207945","article-title":"Cell cycle inhibitors in normal and tumor stem cells","volume":"23","author":"Cheng","year":"2004","journal-title":"Oncogene"},{"key":"10.1016\/j.ejphar.2016.09.006_bib9","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1097\/01.LAB.0000067499.57309.F6","article-title":"Neurokinin-1 receptor expression and its potential effects on tumor growth in human pancreatic cancer","volume":"83","author":"Friess","year":"2003","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ejphar.2016.09.006_bib10","first-page":"118","article-title":"Targeting signaling pathways in acute lymphoblastic leukemia: new insights. ASH Educ. Progr.","volume":"2013","author":"Harrison","year":"2013"},{"key":"10.1016\/j.ejphar.2016.09.006_bib11","doi-asserted-by":"crossref","first-page":"4112","DOI":"10.1200\/JCO.2003.01.095","volume":"21","author":"Hesketh","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib12","doi-asserted-by":"crossref","first-page":"7423","DOI":"10.1128\/MCB.25.17.7423-7431.2005","article-title":"p53-Dependent transcriptional repression of c-myc is required for G1 cell cycle arrest","volume":"25","author":"Ho","year":"2005","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib13","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1007\/s11060-015-1996-6","article-title":"Antitumor action of temozolomide, ritonavir and aprepitant against human glioma cells","volume":"126","author":"Kast","year":"2016","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib14","article-title":"Tumor suppressor genes and ROS: complex networks of interactions","volume":"44","author":"Liu","year":"2012","journal-title":"Free. Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2016.09.006_bib15","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1016\/j.freeradbiomed.2008.01.011","article-title":"ROS and p53: a versatile partnership","volume":"44","author":"Liu","year":"2008","journal-title":"Free Radic. Biol. Med."},{"key":"10.1016\/j.ejphar.2016.09.006_bib16","doi-asserted-by":"crossref","first-page":"137","DOI":"10.3892\/ijo.2013.2164","article-title":"Antitumor activity of neurokinin-1 receptor antagonists in MG-63 human osteosarcoma xenografts","volume":"44","author":"Mu\u00f1oz","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.peptides.2013.07.024","article-title":"Involvement of substance P and the NK-1 receptor in cancer progression","volume":"48","author":"Munoz","year":"2013","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2016.09.006_bib18","first-page":"305","article-title":"Neurokinin-1 receptor: a new promising target in the treatment of cancer","volume":"10","author":"Munoz","year":"2010","journal-title":"Discov. Med."},{"key":"10.1016\/j.ejphar.2016.09.006_bib19","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.3892\/ijo.2014.2565","article-title":"The neurokinin-1 receptor antagonist aprepitant is a promising candidate for the treatment of breast cancer","volume":"45","author":"Mu\u00f1oz","year":"2014","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib20","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/s10637-010-9594-0","article-title":"The NK-1 receptor is expressed in human leukemia and is involved in the antitumor action of aprepitant and other NK-1 receptor antagonists on acute lymphoblastic","volume":"30","author":"Mu\u00f1oz","year":"2012","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejphar.2016.09.006_bib21","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.peptides.2012.09.024","article-title":"The substance P\/neurokinin-1 receptor system in lung cancer: focus on the antitumor action of neurokinin-1 receptor antagonists","volume":"38","author":"Mu\u00f1oz","year":"2012","journal-title":"Peptides"},{"key":"10.1016\/j.ejphar.2016.09.006_bib22","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1007\/s10637-009-9218-8","article-title":"The NK-1 receptor antagonist aprepitant as a broad spectrum antitumor drug","volume":"28","author":"Mu\u00f1oz","year":"2010","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.ejphar.2016.09.006_bib23","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2174\/138945011795528796","article-title":"The NK-1 receptor: a new target in cancer therapy","volume":"12","author":"Munoz","year":"2011","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.ejphar.2016.09.006_bib24","doi-asserted-by":"crossref","first-page":"504","DOI":"10.2174\/092986710790416308","article-title":"A new frontier in the treatment of cancer: NK-1 receptor antagonists","volume":"17","author":"Mu\u00f1oz","year":"2010","journal-title":"Curr. Med. Chem."},{"key":"10.1016\/j.ejphar.2016.09.006_bib25","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1038\/labinvest.2010.92","article-title":"The NK-1 receptor is expressed in human melanoma and is involved in the antitumor action of the NK-1 receptor antagonist aprepitant on melanoma cell lines","volume":"90","author":"Mu\u00f1oz","year":"2010","journal-title":"Lab. Investig."},{"key":"10.1016\/j.ejphar.2016.09.006_bib26","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/sj.leu.2402920","article-title":"Substance P--a potent risk factor in childhood lymphoblastic leukaemia","volume":"17","author":"Nowicki","year":"2003","journal-title":"Leukemia"},{"key":"10.1016\/j.ejphar.2016.09.006_bib27","doi-asserted-by":"crossref","first-page":"1843","DOI":"10.1517\/13543780903379530","article-title":"Tachykinin receptor antagonists in clinical trials","volume":"18","author":"Quartara","year":"2009","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.ejphar.2016.09.006_bib28","first-page":"381434","article-title":"The role of neurokinin-1 receptor in the microenvironment of inflammation and cancer","volume":"2012","author":"Rosso","year":"2012","journal-title":"Sci. World J."},{"key":"10.1016\/j.ejphar.2016.09.006_bib29","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1073\/pnas.97.1.388","article-title":"Increased expression of preprotachykinin-I and neurokinin receptors in human breast cancer cells: implications for bone marrow metastasis","volume":"97","author":"Singh","year":"2000","journal-title":"Proc. Natl. Acad. Sci. USA."},{"key":"10.1016\/j.ejphar.2016.09.006_bib30","doi-asserted-by":"crossref","first-page":"187","DOI":"10.2298\/SARH0804187S","article-title":"Molecular mechanisms involved in chemoresistance in paediatric acute lymphoblastic leukaemia","volume":"136","author":"Stankovic","year":"2008","journal-title":"Srp. Arh. Celok. Lek."},{"key":"10.1016\/j.ejphar.2016.09.006_bib31","doi-asserted-by":"crossref","first-page":"3485","DOI":"10.1128\/MCB.19.5.3485","article-title":"Transcriptional cross talk between NF-\u03baB and p53","volume":"19","author":"Webster","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/j.ejphar.2016.09.006_bib32","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1529\/biophysj.105.077693","article-title":"Akt versus p53 in a network of oncogenes and tumor suppressor genes regulating cell survival and death","volume":"91","author":"Wee","year":"2006","journal-title":"Biophys. J."},{"key":"10.1016\/j.ejphar.2016.09.006_bib33","first-page":"366","article-title":"Pediatric acute leukemia therapies informed by molecular analysis of high-risk disease. ASH Educ. Progr.","volume":"2011","author":"Winter","year":"2011"},{"key":"10.1016\/j.ejphar.2016.09.006_bib34","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1096\/fasebj.14.2.379","article-title":"Coordinate modulation of Sp1, NF-kappa B, and p53 in confluent human malignant melanoma cells after ionizing radiation","volume":"14","author":"Yang","year":"2000","journal-title":"FASEB J."}],"container-title":["European Journal of Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916305672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014299916305672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,11,1]],"date-time":"2019-11-01T07:41:15Z","timestamp":1572594075000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014299916305672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11]]},"references-count":34,"alternative-id":["S0014299916305672"],"URL":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.09.006","relation":{},"ISSN":["0014-2999"],"issn-type":[{"value":"0014-2999","type":"print"}],"subject":[],"published":{"date-parts":[[2016,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Inhibition of tachykinin NK1 receptor using aprepitant induces apoptotic cell death and G1 arrest through Akt\/p53 axis in pre-B acute lymphoblastic leukemia cells","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejphar.2016.09.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}